Abstract

Jingjing Liu and Youn Jin Choi*

Ovarian Cancer (OC) is the most lethal gynecologic malignancy but a timely diagnosis is limited because of the absence of effective biomarkers. Germline BRCA1/2 genetic alterations are risk factors for hereditary OC and a Risk-Reducing Salpingo-Oophorectomy (RRSO) is pursued to prevent disease. However, not all healthy carriers develop the disease and RRSO may cause complications such as menopausal symptoms and cardiac risks. In addition, RRSO may not prevent BRCA1/2-related primary peritoneal cancer. Therefore, it is necessary to find biomarkers for ‘selective’ RRSO and chemoprevention strategies against hereditary OC.